Oncolytics Biotech Inc. received written feedback from the U.S. Food and Drug Administration regarding the design of a potential pivotal Part B expansion of its ongoing REO 033 study for second-line RAS-mutant, microsatellite stable metastatic colorectal cancer. The FDA aligned with the company's proposal to use objective response rate for accelerated approval and progression-free survival for full approval. Oncolytics elected to forego a scheduled Type D meeting in favor of an End-of-Phase meeting to finalize registration program elements. This regulatory alignment supports the potential transition from Part A to a pivotal Part B study upon availability of interim clinical data, potentially accelerating the path to market for pelareorep. Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an investigational immunotherapy for cancer treatment.

On July 20, 2026, Oncolytics Biotech Inc. received notification from Nasdaq that its common stock failed to meet the $1.00 minimum bid price requirement after closing below that level for 30 consecutive business days. The company has a compliance period until January 19, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. Failure to regain compliance may lead to delisting, although an additional 180-day extension may be available if certain criteria are met. The company is currently assessing options to maintain its listing. This company is a biotechnology firm that develops immunotherapies for the treatment of cancer.

Oncolytics Biotech Inc. announced that the FDA has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for treating inoperable, locally recurrent or metastatic squamous cell carcinoma of the anal canal. This designation facilitates expedited review and more frequent interactions with the FDA. The company is targeting an estimated $1 billion annual U.S. commercial opportunity. Oncolytics Biotech Inc. is a clinical-stage immunotherapy company developing investigational RNA immunotherapeutic agents for gastrointestinal cancers.

Oncolytics Biotech Inc. announced updates and progress regarding its REO 033 study and plans to hold a Type D meeting with the U.S. Food and Drug Administration to discuss registrational expansion and study design elements. Oncolytics Biotech Inc. is a biotechnology company focused on developing oncology immunotherapy treatments.

On July 6, 2026, Oncolytics Biotech Inc. disengaged Ernst & Young LLP as its independent registered public accounting firm and engaged Baker Tilly US, LLP for the 2026 fiscal year. The change was driven by corporate restructuring. The company reported no disagreements with Ernst & Young regarding accounting principles, practices, or auditing procedures, although previous reports included an explanatory paragraph regarding the company's ability to continue as a going concern. The company operates in the biotechnology industry and develops immunotherapies for the treatment of cancer.